Holen Sie sich die Stockscreener-App
2.61
7.41%
0.18
Handel nachbörslich:
2.61
Schlusskurs vom Vortag:
$2.43
Offen:
$2.44
24-Stunden-Volumen:
478.73K
Relative Volume:
1.55
Marktkapitalisierung:
$151.10M
Einnahmen:
$59.62M
Nettoeinkommen (Verlust:
$8.57M
KGV:
21.93
EPS:
0.119
Netto-Cashflow:
$-12.62M
1W Leistung:
+16.52%
1M Leistung:
+13.48%
6M Leistung:
+24.88%
1J Leistung:
+348.45%
1-Tages-Spanne:
$2.44
$2.61
1-Wochen-Bereich:
$2.21
$2.61
52-Wochen-Spanne:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.61 | 140.68M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives - Sahm
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print - Investing.com
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - Bitget
Spero Therapeutics earnings beat by $0.73, revenue topped estimates - Investing.com Canada
SPERO THERAPEUTICS ($SPRO) Releases Q4 2025 Earnings - Quiver Quantitative
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS - MarketBeat
Spero Therapeutics Q4 revenue nearly triples, swings to profit - TradingView
Spero Therapeutics 2025 10-K: $66.8M Revenue, $0.15 EPS - TradingView
Spero Therapeutics (NASDAQ: SPRO) turns 2025 profit as tebipenem advances - Stock Titan
[10-K] Spero Therapeutics, Inc. Files Annual Report - Stock Titan
Can Spero Therapeutics Inc sustain earnings growth2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - MSN
Analyst Calls: Is Spero Therapeutics Inc stock showing strong momentumWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
If You Invested $1,000 in Spero Therapeuti (SPRO) - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Spero Therapeutics (SPRO.US) will release its earnings report after the market closes on March 26. - 富途牛牛
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Activity Recap: Is Spero Therapeutics Inc stock showing strong momentumPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday - MarketBeat
Spero Therapeutics Inc 預計每股虧損 55 美分財報前瞻 - TradingView
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - marketscreener.com
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Weekly Earnings: What are Spero Therapeutics Incs recent SEC filings showingQuarterly Trade Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest - MarketBeat
Profit Recap: Is Spero Therapeutics Inc stock showing strong momentumStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Spero Therapeutics Inc erwartet einen Verlust von 55 Cents pro AktieEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Dow Update: Can Spero Therapeutics Inc lead its sector in growth2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Stock Recap: Can Spero Therapeutics Inc ride the EV waveMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Big Picture: Will Spero Therapeutics Inc benefit from seasonalityWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0% - MarketBeat
SPRO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock sustain margin levels2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Aug PostEarnings: Can Spero Therapeutics Inc sustain earnings growth2025 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
Valuation Update: Is Spero Therapeutics Inc stock showing strong momentum2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st
Is Spero Therapeutics Inc. a good stock for dollar cost averaging2025 Price Targets & Weekly High Potential Stock Alerts - mfd.ru
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock - MarketBeat
Keutzer, Spero Therapeutics COO, sells $44k in shares - Investing.com
Spero Therapeutics CEO sells $207k in stock By Investing.com - Investing.com Canada
Keutzer, Spero Therapeutics COO, sells $44k in shares By Investing.com - Investing.com Canada
Spero Therapeutics CEO sells $207k in stock - Investing.com
Aug Breakouts: What drives Spero Therapeutics Incs stock priceEarnings Summary Report & Safe Entry Zone Tips - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares - MarketBeat
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spero Therapeutics Inc-Aktie (SPRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):